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INTRODUCTION AND OBJECTIVES 
When administering intravenous fluids or medications, it is 
difficult to maintain a constant rate of flow using standard infusion 
sets. Inexperienced personnel may find flow regulating clamps diffi-
cult to set, and an improper adjustment may result in a large error 
in the infusion rate. Changes in fhe patient's venous pressure may 
result in variations in flow rate. Because of difficulties in main-
taining desired rates of intravenous infusion, devices which closely 
control intravenous fluid administration have been developed over the 
last two decades. 
A variety of infusion pumps and flow rate regulators are avail-
able for administration of parenteral infusions. Infusion rate regu-
lators control infusion rate while relying on a gravity-fed infusion. 
Infusion pumps will pump fluid against a pressure gradient, providing 
sufficient force to pump fluid through a filter or into an arterial 
line. The syringe pump was one of the earliest types of infusion 
pumps. A synchronous motor drives the syringe, resulting in fluid 
being expelled slowly from the syringe. Two other basic types of 
infusion pumps are currently in use. Volumetric pumps have a metered 
chamber as a part of the fluid pathway of the administration set. A 
piston produces pressure within a cylinder sufficient to expel fluid 
from the cylinder. The nonvolumetric peristaltic infusion pump forces 
fluid through the administration set tubing as a result of the move-
ment of the wall of the pumping chamber. In rotary peristaltic. 
2 
pumping, the pumping chamber is arranged in a semicircle with a roller 
propelling fluid through the tubing. Most linear peristaltic pumps 
have a row of "fingers" which sequentially press the tubing so that 
1 2 
fluid is propelled through the chamber. ' 
* 
The 3M Small Volume Infusion (SVI) system is a portable small 
volume infusion system which has been recently marketed by the 3M 
Company (St. Paul, MN). The 3M SVI 'system is designed to deliver 
small volumes of fluid intravenously from syringes at controlled rates 
of flow. This infusion system consists of a mechanically powered in-
fuser (10 x 2 inch square) and a calibrated flow regulating set. The 
3M SVI infuser is reuseable and mechanically driven by spring loading, 
9 
thereby not requiring a battery or electrical power source. The in-
fuser applies constant pressure to a syringe, with flow rate regulat-
ed by disposable infusion sets available in a range of calibrated 
flow rates (0.5, 1, 10, or 30 ml/hr). This allows selection of ap-
propriate flow rate for the medication or fluid being administered, 
or changing the rate of flow while using the same infuser. 
Medical devices, including infusion pumps, marketed after May 
26, 1976, must undergo safety and efficacy testing prior to market-3 
ing. Therefore, this study was designed as an open trial to evaluate 
the safety and accuracy of the 3M SVI in surgical intensive care 
patients. Data were collected in a prospective manner to evaluate 1) 
flow rate accuracy of the 3M SVI system for a variety of parenteral 
fluids and medications, and 2) safety and dependability of this small 
volume infusion system. 
•k 




Patients eligible for study were those in the University of Utah 
Hospital Surgical Intensive Care Unit and recipients of intravenous 
therapy. Patients were included if the surgical staff felt the abili-
ty to control the infusion rate and/or minimize fluid volume would be 
beneficial. Only patients receiving drugs not requiring changes in 
infusion rate during administration were entered. Informed written 
consent was obtained from each participating patient or legal guard-
ian. 
Infusion System 
An intravenous cannula was placed (if not already in place) in a 
superficial vein, with gauge and length appropriate for venipuncture 
location. 
Medication to be administered was prepared in the appropriate 
concentration and volume and drawn into a Burron syringe. Burron 
syringes were recommended by 3M since this brand had been used in 
preliminary testing and consistent accuracy could be guaranteed. The 
drug concentration was not to exceed 10 percent since it was con-
sidered possible that concentrations exceeding this could result in 
fluid viscosity high enough to impair flow through the device. 
The desired flow regulating set was attached to the syringe. The 
set was purged and syringe volume subsequently adjusted. The syringe 
with regulating set attached was then placed into the open infuser 
and snapped into clamps. The 3M SVI regulating set was connected 
4 
directly to the patient's intravenous cannula or used in tandem with 
standard intravenous primary tubing for "piggyback" administration. 
Under some circumstances two SVI sets were run in tandem. The infuser 
was started by closing the cover, and stopped by opening the cover. 
All syringes, infusers, and flow controllers were provided by 
the 3M Company. 
** 
Data Collection 
This study required collectioif of quantitative data (syringe 
volume) obtained through observation of each infusion, and qualita-
tive information related to patient safety (phlebitis, adverse re-
actions) and equipment dependability (malfunction). 
One of the investigators recorded the fluid volumes remaining in 
the syringe at multiple times during each infusion trial. Observa-
tion times and data were recorded for each trial. Other data col-
lected included application (i.e., direct, "piggyback"), type of 
cannula, presence or absence of an armboard, medication name and con-
centration, infusion rate selected, and infuser and regulating set 
serial numbers. These data are tabulated for each infusion trial in 
the Appendix. 
The presence or absence of adverse reactions and system mal-
function were also noted. In addition, the venipuncture site was in-
spected and scored for phlebitis using the following rating scheme: 
a. No reaction 
Site appeared equivalent to surrounding normal skin 
b. Pain at site 
Patient perceived pain when skin proximal to venipuncture was 
palpated 
5 
c. Pain and erythema 
Patient perceived pain when venipuncture site was palpated 
and skin reddened 
d. Pain/erythema/streaking of skin 
Patients perceived pain when skin proximal to venipuncture 
site was palpated, skin reddened and vein felt hardened to 
touch 
e. Infiltration 
Erythema, swelling and tenderness occurred proximal to 
venipuncture site 
Data Analysis 
Linear regression analysis was performed to determine the ob-
served flow rate for each infusion trial and accuracy was determined 
by comparing the observed flow rate to the selected flow rate. The 
incidence of phlebitis, other adverse reactions and equipment mal-
function were determined. 
RESULTS 
Forty-one infusion trials were carried out in six patients. 
Patient characteristics are summarized in Table I. Medications and 
intravenous fluids administered by the 3M SVI system included amino-
phylline, normal saline, heparin, cimetidine, clindamycin, gentamicin, 
calcium gluconate, and cephapirin. 
Twenty-six infusions, including aminophylline, heparin, normal 
saline and calcium gluconate were administered at a rate of 1 ml/hr. 
The raw data and a summary of these data are shown in Tables II and 
III, respectively, and graphically depicted in Figure I. The mean 
(± standard deviation [SD]) observed infusion rate for these 26 trials 
was 1.1 ± 0.1 ml/hr. Observed infusion rates ranged from 0.9 to 1.3 
ml/hr. Sixteen of the 26 trials (62 percent) were associated with 
6 
10 percent or less error, and 24 of the 26 (92 percent) with less than 
or equal to a 20 percent error. Sixty-nine percent (18) of these 26 
infusions ran faster than the intended 1 ml/hr rate. Four percent 
(1) ran slower than 1 ml/hr, while 27 percent (7) ran at 1 ml/hr. 
Nine infusions, including cimetidine, clindamycin, and cepha-
pirin, were administered at a rate of 10 ml/hr. The raw data are 
shown in Table IV and summarized in'Table V. The mean (±SD) observed 
infusion rate was 8.4 ± 2.8 ml/hr, with a range of 1.7 to 11 ml/hr. 
Two-thirds (6) of these infusions ran within 10 percent error, while 
one-third (3) were associated with greater than 20 percent error. 
Sixty-seven percent (6) of these trials ran slower than the intended 
9 
10 ml/hr, while 33 percent (3) ran faster. 
Five infusions, including cimetidine and gentamicin, were ad-
ministered at a rate of 30 ml/hr. The raw data and a summary of 
these data are shown in Tables VI and VII, respectively. The mean 
(±SD) observed infusion rate for this set of trials was 29.7 ±3.2 
ml/hr. Four of the five infusions (80 percent) ran with 10 percent 
or less error. All five infusions were associated with an error of 
20 percent or less. Eighty percent (4) of the trials ran at a rate 
slower than 30 ml/hr, while one ran faster. 
Aminophylline was the medication given most often by the 3M SVI 
system in this series. All aminophylline infusions were administered 
at a rate of 1 ml/hr and in a concentration of 10 or 25 mg/ml. The 
mean (±SD) observed infusion rate for these 16 aminophylline infusions 
was 1.1 ± 0.1 ml/hr. Aminophylline data are summarized in Table VIII. 
Overall, 26 (65 percent) of the 40 infusions in this series were 
associated with an error of 10 percent or less. Thirty-five (88 per-
cent) varied 20 percent or less from the intended infusion rate. 
Eleven of the 40 infusions (27.5 percent) ran slower than the selected 
rate, while 22 (55 percent) ran faster. 
In this series there were three trials in which numerous readings 
were taken over more than six hours'.^  In each of these cases, the SVI 
system appeared to deliver medication at a constant rate throughout 
the trial. A graphic analysis of these data is shown in Figures II -
IV. 
A malfunction of the infusion system occurred in one of the 41 
9 
trials. In this case, the infusion ran at 1 ml/hr rather than at 10 
<t 
ml/hr as intended. The catheter was checked and found to be patent. 
After the flow rate controller was changed, the infusion ran well. 
It is possible that the controller was mislabeled as 1 ml/hr rather 
than 10 ml/hr. 
One patient experienced pain at the catheter site during a 
single 3M SVI infusion. The pain subsided following the trial. No 
other adverse reaction was noted. The infusion of higher concen-
trations than commonly used in clinical practice, such as aminophyl-
line 25 mg/ml, did not result in an increased incidence of pain at the 
site of injection. This may be due to the slow rates of flow main-
tained in this study. 
DISCUSSION 
Intravenous infusion pumps are useful when the control of flow 
rate or volume is desired. The 3M SVI system offers a unique 
8 
alternative to other infusion pumps currently in use. The device pro-
vides a method of administering small volumes of intravenous fluids at 
a controlled rate. The SVI system is dependable, easy to operate, 
portable, and requires no external power source. 
4 
A recent study evaluated the 3M SVI system in pediatric patients. 
In that investigation, aminoglycoside antibiotics, heparin solutions 
and intravenous fluids were administered to pediatric and neonatal 
patients. Forty-seven infusions were given at a predetermined rate 
of 1 ml/hr. The range of observed rates was 0.6 to 1.47 ml/hr, with 
the percent error ranging from -40 to 47 percent. The majority of 
infusions ran within 10 percent of the predicted 1 ml/hr flow rate. 
9 
Fifty-one infusions were administered at a rate of 10 ml/hr. The ob-
<t 
served flow rates varied from 7.88 to 12.48 ml/hr, with percent error 
ranging from -20 to 25 percent. Approximately 70 percent of these 
infusions ran within 10 percent of the predicted rate. The SVI sys-
tem was found to be a safe, effective method for the administration 
of these agents. No adverse reactions and one malfunction were re-
ported with 113 infusions. 
This series of 41 infusions in six surgical intensive care 
patients also found the 3M SVI system to be a safe and dependable 
method for the administration of intravenous fluids and medications. 
One malfunction was noted and one patient reported pain at the site 
of injection during one infusion trial. 
Infusions set to run at 1 ml/hr were observed to flow at rates 
ranging from 0.9 to 1.3 ml/hr, with error ranging from -10 to 30 per-
cent. This range is smaller than that reported for the 1 ml/hr in-
» 
fusions in the pediatric study. 
Two of these infusions, the cephapirin infusion (#218) and one 
clindamycin infusion (#148), were mixed in a concentration greater 
than the 10 percent recommended (20 percent and 12 percent, respective-
ly). These highly concentrated solutions may explain the unusually 
slow observed infusion rates for these two trials. When the data ob-
tained from these two infusions are deleted, the mean observed in-
fusion rate for the 10 ml/hr trials'pas 9.8 ± 1.0 ml/hr, ranging from 
7.9 to 11 ml/hr. Once again this is a narrower range than previously 
reported. 
The data from 30 ml/hr infusions indicate that the SVI system 
allowed administration of fluids at this flow rate with about the 
same degree of accuracy as at 1 ml/hr and 10 ml/hr. The range of ob-
served rates was 27.1 to 36 ml/hr and all infusions at this rate ran 
within 20 percent of the predicted 30 ml/hr. 
The importance of the variation in observed infusion rates will 
depend upon the clinical situation in which the SVI system is used. 
When this infusion system is utilized to keep an intravenous line or 
dialysis shunt open with small volumes of dilute heparin solution or 
normal saline, the variation of up to 30 percent observed in this 
study is unlikely to present a problem. 
The majority of trials in this series involved the administration 
of aminophylline by constant intravenous infusion. Although amino-
phylline infusion rates varied from 1 ml/hr by up to 30 percent in 
patient J.L., this patient did not exhibit any signs of theophylline 
toxicity and had serum theophylline levels within the therapeutic 
range while receiving the drug by the 3M SVI system. However, based 
10 
on the pharmacokinetics of theophylline, it is possible that such a 
variation in infusion rates could result in meaningful variations in 
serum theophylline concentrations. The clinician must consider such 
potential variations in flow rate when using the 3M SVI system. 
The 3M SVI system is most useful in situations where continuous 
infusion of a single medication concentration is indicated. Medi-
cations, such as nitroprusside, which m a Y require frequent changes in 
administration rate would be best administered by other available 
infusion pumps. 
Another situation in which the 3M SVI system may be found very 
useful is when fluid restriction is desired. This small volume in-
9 
fusion system can administer doses of medication in fluid volumes 
smaller than generally prepared for "piggyback" administration. 
Patient I.G. was in acute renal failure during this study. Therefore, 
an attempt was made to restrict fluids in this patient. Both clinda-
mycin and cimetidine were to be administered every six hours. Under 
normal circumstances, the administration of these medications would 
have involved giving the patient 600 ml of fluid over each 24 hour 
period. If a request had been made to the pharmacy to minimize fluid 
volume, 200 ml would have been administered daily with these medica-
tions. Using the 3M SVI system, only 40 ml of fluid was required to 
administer these eight daily doses. 
An obvious advantage of the 3M SVI system is the simplicity of 
its operation. The device may prove useful in the home administration 
of antibiotics in patients requiring long term intravenous antimicrobi-
al therapy. 
11 
Preliminary trials with the SVI system indicate that the device 
delivers intravenous fluids at a constant rate over a 10 hour period. 
The three trials in this series during which numerous readings were 
taken over more than six hours confirm that the flow rate is constant 
over time. 
Considering these results, the comparative cost with other in-
fusion pumps, and the simplicity of * operation, this system offers a 
safe and dependable alternative method for the administration of in-
travenous fluids and a select group of drugs requiring a controlled 
infusion rate. This system may be particularly useful where fluid 
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Observed Infusion Rate (ml/hr) 
Figure I. Graphical presentation of observed infusion 




Time Into Infusion (ml) 
Figure IV. Graph of the data obtained during infusion 
trials 144 and 149 indicating a constant rate of flow 










Problem List Number of SVI Infusions Drug(s) Administered by SVI 
Adenocarcinoma of the rectum 16 Aminophylline 
Benign prostatic hypertrophy 
Acute renal failure 
Rule out tuberculosis 
Recurrent urinary tract infection 
Neurogenic bladder 
Bowel perforation 
Multiple intraloop bowel abcesses 
Sepsis 
Acute renal failure 
Seizures 








Acute diverticulitis 2 Cimetidine 
Exploratory laparotomy 
Steroid dependent rheumatoid 
arthritis 
Rheumatoid arthritis 1 Gentamicin 
Leg ulcers - debridement 
Duodenal perforation 
Peptic ulcer disease 
* 
Status-post gastroplasty 1 Cephapirin 
Anastomotic leak 
Left upper quadrant abcess 
Wound infection 
TABLE I (continued) 
Initials Age Problem List Number of SVI Infusions Drug(s) Administered by SVI 
D.H. 58 Hickman catheter sepsis 2 Cimetidine 
Short bowel syndrome 
Duodenocolostomy 
Transurethral prostatic resection 
All patients were in the Surgical Intensive Care Unit at the University of Utah Medical Center. 
TABLE II 
20 
3M SVI INFUSION DATA - 1 ml/hr 
Record 
Serial 






201 J.L. Aminophylline 25 mg/ml 1.2 20 
202 J.L. Aminophylline 25 mg/ml 1.0 0 
203 J.L. Aminophylline 25 mg/ml 1.1 10 
204 J.L. Aminophylline 25 mg/ml 1.1 10 
205 J.L. Aminophylline 25 mg/ml 1.3 30 
206 J.L. Aminophylline 25 mg/ml 1.1 10 
207 J.L. Aminophylline 25 mg/ml* 1.2 20 
208 J.L. Aminophylline 25 mg/ml 1.3 30 
209 J.L. Aminophylline 10 mg/ml 1.2 20 
210 J.L. Aminophylline 25 mg/ml 1.2 20 
211 J.L. Aminophylline 25 mg/ml 1.2 20 
212 J.L. Aminophylline 10 mg/ml^ 1.2 20 
213 J.L. Aminophylline 10 mg/ml 1.1 10 
214 J.L. Aminophylline 25 mg/ml 1.1 10 
215 J.L. Aminophylline 25 mg/ml 1.0 0 
216 J.L. Aminophylline 25 mg/ml 1.0 0 
127 I.G. Normal Saline 1.2 20 
130 I.G. Calcium Gluconate 0.47 mEq/ml 0.9 -10 
136 I.G. Normal Saline 1.0 0 
*137 I.G. Normal Saline 1.1 10 
139 I.G. Heparin 200 U/ml 1.1 10 
141 I.G. Heparin 200 U/ml 1.0 0 
144 I.G. Heparin 200 U/ml 1.1 10 
147 I.G. Normal Saline 1.0 0 
149 I.G. Heparin 200 U/ml 1.0 0 
150 I.G. Heparin 200 U/ml 1.2 20 
*Patient experienced pain at site of injection 
TABLE III 
SUMMARY 
3M SVI INFUSION DATA - 1 ml/hr 
Total Number of Infusion Trials: 26 
16 Aminophylline * 
5 Heparin 
4 Normal Saline 
1 Calcium Gluconate 
Mean (± SD) Observed Infusion Rate = 1.1 ± 0.1 ml/hr 
Range of Observed Infusion Rates: 0.9 to 1.3 ml/hr 




1/26 ( 4%) 
7/26 (27%) 
17/26 (69%) 






3M SVI INFUSION DATA - 10 ml/hr 
Record 
Serial 








Cimetidine 60 mg/ml' 10.2 2 
128 I.G. Clindamycin 30 mg/ml 10.9 9 
131 I.G. Clindamycin 60 mg/ml 9.3 -7 
133 I.G. Cimetidine 60 mg/ml 11.0 10 
134 I.G. Clindamycin 60 mg/ml 9.4 -6 
• <r 
135 I.G. Clindamycin 60 mg/ml 
t 
7.9 -21 
138 I.G. Clindamycin 60 mg/ml 9.6 -4 
146 I.G. Clindamycin 120 mg/ml 1.0 -90 
+148 • I.G. Clindamycin 120 mg/ml 5.6 -44 
+218 S.B. Cephapirin 200 mg/ml 1.7 -83 
* 
+ 
SVI malfunction - data deleted from analysis 




3M SVI INFUSION DATA - 10 ml/hr 
Total Ntimber of Infusion Trials: '9 
6 Clindamycin 
2 Cimetidine * 
1 Cephapirin 
Mean (± SD) Observed Infusion Rate = 8.4 ± 2.8 ml/hr 
Range of Observed Infusion Rates: 1.7 to 11.0 ml/hr 
* 
Observed Infusion Rate 
The cephapirin infusion (#218) and one clindamycin infusion 
(#148) were mixed in a concentration exceeding the recom-
mended 10%, which may explain the unusually slow observed 
infusion rates. When the data from these two infusions are 
deleted: 
Mean (± SD) Observed Infusion Rate = 9.8 ± 1.0 ml/hr 












3M SVI INFUSION DATA - 30 ml/hr 
Record . Observed 
Serial " Infusion Percent 
Number Patient Drug Rate (ml/hr) Error 
142 V.B. Cimetidine 30 mg/ml 27.1 -10 
145 V.B. Cimetidine 30 mg/ml 28.1 -6 
217 C.B. Gentamicin 8 mg/ml 27.8 -7 









3M SVI INFUSION DATA - 30 ml/hr 
Total Number of Infusion Trials: 5 
4 Cimetidine 
1 Gentamicin 
Mean (± SD) Observed Infusion Rate = 29.7 ± 3.2 ml/hr 
» 
Range of Observed Infusion Rates: 27.1 to 36.0 ml/hr 













3M SVI INFUSION DATA - AMINOPHYLLINE (1 ml/hr) 
Total Number of Infusion Trials: 16 
13 at 25 mg/ml concentration 
3 at 10 mg/ml concentration 
Mean (± SD) Observed Infusion Rate = 1.1 ± 0.1 ml/hr 
Range of Observed Infusion Rates: 1.0 to 1.3 ml/hr 




0/16 ( 0%) 
3/16 (19%) 
13/16 (81%) 








DATA COLLECTED FOR INDIVIDUAL INFUSION TRIALS 
Serial 
Number Application Date 
Patient J.L. 
201 Direct, continuous infusion 9/ 6/79 
202 Direct, continuous infusion 9/ 6/79 
203 Direct, continuous infusion 9/ 6/79 
204 Direct, continuous infusion 9/ 6/79 
205 Direct, continuous infusion 9/ 7/79 
206 Direct, continuous infusion 9/ 7/79 
Syringe 
Time Volume (ml) Armboard Cannula 












1:52P 4.8 No 20G catheter 
2:57P 3.6 
4:15P 2.2 












207 Direct, continuous infusion 
208 Direct, continuous infusion 
209 Direct, continuous infusion 
210 Direct, continuous infusion 
211 Direct, continuous infusion 
212 Direct, continuous infusion 
213 Direct, continuous infusion 





















































































208 Direct, continuous infusion 
209 Direct, continuous infusion 
210 Direct, continuous infusion 
211 Direct, continuous infusion 
212 Direct, continuous infusion 
213 Direct, continuous infusion 



















































































215 Direct, continuous infusion 
216 Direct, continuous infusion 
Patient I.G. 
126 Piggyback into primary set 
127 Direct, KVO* continuous infusion 
128 Piggyback into 3M SVI set 
130 Direct, KVO continuous infusion 
















8/ 7/79 11:26A 
12:01P 
12:1 IP 





Volume (ml) Armboard Cannula 
7.8 No 20G catheter 
5.8 
4.1 
9.0 No 20G catheter 
7.6 




9.5 No Swan Ganz 
8.6 catheter 
8.0* x v 
5.8 
9.4 No Swan Ganz 
3.0 catheter 
1.2 







Number Application Date 
131 Piggyback into 3M SVI set 8/ 8/79 
133 Piggyback into 3M SVI set 8/10/79 
134 Piggyback into 3M SVI set 8/10/79 
135 Piggyback into primary set 8/14/79 
136 Direct, KVO continuous infusion 8/14/79 
137 Direct, KVO continuous infusion 8/15/79 
138 Piggyback into 3M SVI set 8/15/79 
Syringe 
Time Volume (ml) Armboard Cannula 
3:49P 4.5 No Swan Ganz 
4:02P 2.4 catheter 
4:05P 2.0 
4: IIP 1.0 




10:00A 5.0 No catheter 
10:15A 2.6 
10:19A 2.0 
9: 57A 4.3 No catheter 
10:15A 1.8* 
10:20A 1.2 \ 
















Direct, KVO continuous infusion 




141 Direct, KVO continuous infusion 
for dialysis shunt 
8/16/79 
144 Direct, KVO continuous infusion 8/17/79 
for dialysis shunt 
146 Piggyback into 3M SVI set 
147 Direct, KVO continuous infusion 
8/17/79 
8/17/79 
148 Piggyback into 3M SVI set 8/17/79 
149 Direct, KVO continuous infusion 8/17/79 
for dialysis shunt 
150 Direct, KVO continuous infusion 8/21/79 
for dialysis shunt 
Syringe 
Volume (ml) Armboard Cannula 
8.0 No catheter 
6 . 8 
6.4 
5.6 No catheter 
5.2 
4.5 
7.2 No catheter 
6.6 
4.5 
4.0 No 20G catheter 
3.5 
3.4 




2.8 No catheter 
2.2 
1.6 
2.4 No catheter 
0.4 










Volume (ml) Armboard Cannula 
Patient D.H. 
221 Piggyback into primary set 1/22/80 
222 Piggyback into primary set 1/18/80 
Patient S.B. 
218 Piggyback into primary set 10/ 2/79 
Patient C.B. 
217 Direct infusion 9/25/79 
Patient V.B. 
142 Direct infusion 8/16/79 









8:40A 5.5 \* No catheter 
9:14A 4.5 
9:50A 3.5 
3:49P 8.8 No catheter 
3:55P 5.8 
4:02P 2.8 





Number Application Date Time 
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